Pulmonary Arterial Hypertension Market to Grow with a CAGR of 6.32% through 2030
Rise in prevalence of lung cancer and lung-related disorders is the major drivers for the Global Pulmonary Arterial Hypertension Market growth in the forecast period, 2026-2030.
According to TechSci Research
report, “Pulmonary Arterial Hypertension Market –Global Industry Size, Share, Trends, Competition,
Opportunity and Forecast, 2026-2030”, the Global
Pulmonary Arterial Hypertension Market was valued at USD 8.29 billion in 2024 and is anticipated to project robust growth in the forecast period with a CAGR
of 6.32% through 2030. This can be ascribed to collaborations and partnerships
among leading companies with a diverse approach to merge the expertise of
individual companies and to strengthen their position in the market.
The rising prevalence of lung cancer and other lung-related disorders is a significant driver of the global Pulmonary Arterial Hypertension (PAH) market. Lung cancer, one of the leading causes of cancer-related deaths worldwide, has been increasingly linked with secondary complications such as PAH. As tumor growth and metastatic spread often affect pulmonary vessels, patients may experience elevated pulmonary artery pressures, further complicating treatment and reducing survival outcomes. This growing association between lung malignancies and PAH is pushing oncologists and pulmonologists to closely monitor for PAH symptoms and adopt specialized treatment regimens to manage this dual burden effectively.
Beyond cancer, chronic respiratory diseases like chronic obstructive pulmonary disease (COPD), interstitial lung disease (ILD), and idiopathic pulmonary fibrosis (IPF) are also major contributors to the development of PAH. According to the Global Burden of Disease data, chronic respiratory conditions are among the top causes of disability-adjusted life years (DALYs) globally. These lung disorders often result in long-term damage to pulmonary vasculature, leading to the progressive rise in pulmonary pressure. The increasing incidence of these conditions—driven by air pollution, smoking, occupational hazards, and aging populations—has resulted in a growing pool of patients at risk of developing PAH, thereby accelerating market demand for diagnostics and therapeutics.
The growing recognition of the relationship between lung diseases and PAH has led to significant improvements in disease screening and management. Physicians are now more vigilant in screening high-risk patients, especially those with underlying lung pathology. This proactive approach is increasing the rate of early diagnosis and intervention, thereby improving patient outcomes and expanding the treated patient population. Additionally, pharmaceutical companies are investing in research and development of novel PAH therapies tailored for patients with coexisting lung disorders, further fueling innovation and growth within the PAH market. As awareness spreads, the healthcare ecosystem is becoming increasingly focused on integrated care models that address both primary lung conditions and associated PAH.
Browse over XX market data Figures and spread through XX Pages and an in-depth TOC on "Global Pulmonary Arterial Hypertension Market”
The Global Pulmonary
Arterial Hypertension Market segmentation is based on By Drug Class, Type, Route
Of Administration, Company, and Region.
Based on drug class, Phosphodiesterase 5 (PDE5) inhibitors are expected to witness the fastest growth in the Pulmonary Arterial Hypertension (PAH) market due to their proven efficacy, ease of oral administration, and favorable safety profile. These drugs, such as sildenafil and tadalafil, work by relaxing the pulmonary blood vessels, reducing arterial pressure, and improving exercise capacity and overall quality of life in PAH patients. Growing physician preference, patient compliance, and expanding clinical evidence supporting long-term use are fueling their adoption. Additionally, the increasing availability of generics is further accelerating their uptake in cost-sensitive markets.
Based on region, Asia-Pacific is expected to grow swiftly in the Pulmonary Arterial Hypertension (PAH) market due to rising awareness, improving diagnostic capabilities, and increasing government healthcare initiatives across countries like China, India, and Japan. The growing burden of respiratory diseases and a large undiagnosed patient population are driving the demand for early diagnosis and effective treatments. Expansion of healthcare infrastructure, increased investment in rare disease research, and wider access to advanced therapies are enhancing market penetration. Collaborations between global pharmaceutical firms and local companies are also accelerating product availability and regulatory approvals.
Some of the major
companies operating in the Global Pulmonary Arterial Hypertension Market include:
Download Free Sample Report
Customers can also request for 10% free customization on this report.
“Medical devices such as pulmonary vasodilator pumps and implantable devices like ventricular assist devices contribute to the management of severe cases of PAH. In addition to conventional therapies, lifestyle modifications and regular exercise are recommended to improve patients' quality of life. However, challenges persist in the PAH market, including the high cost of treatment and limited accessibility to specialized care. Moreover, the complexity of PAH diagnosis and the need for specialized expertise can hinder timely intervention. The market's outlook is characterized by ongoing research and development efforts aimed at finding novel therapies and improving treatment outcomes. The emergence of personalized medicine approaches, biomarker identification, and the exploration of combination therapies hold promise for tailoring treatments to individual patients' needs. In conclusion, the Global Pulmonary Arterial Hypertension Market is undergoing transformation with the advent of innovative therapies and medical advancements. As awareness of the condition grows and research continues, the market is poised to witness further developments in diagnostics, treatment options, and patient care, ultimately improving the lives of those affected by this challenging medical condition", said Mr. Karan Chechi, Research Director of TechSci Research, a research-based Global management consulting firm.
"Pulmonary Arterial Hypertension Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Class (Prostacyclin and Prostacyclin Analogs, Calcium Channel Blockers, Phosphodiesterase 5, Endothelin Receptor Antagonist and Others), By Type (Branded, Generics), By Route of Administration (Oral, Intravenous/ Subcutaneous, Inhalational), By Region and Competition, 2020-2030F", has evaluated the future
growth potential of Global Pulmonary Arterial Hypertension Market and provides
statistics & information on market size, structure, and future market
growth. The report intends to provide innovative market intelligence and help
decision makers take sound investment decisions. Besides, the report also
identifies and analyzes the emerging trends along with essential drivers,
challenges, and opportunities in Global Pulmonary Arterial Hypertension Market.
Contact
TechSci Research LLC
420 Lexington Avenue, Suite 300,
New York, United States- 10170
M: +13322586602
Email: [email protected]
Web: https://www.techsciresearch.com